文献速递甲状腺与颈部外科

全甲状腺切除术比放射性碘治疗更具成本效益:格雷夫斯病替代抗甲状腺药物的选择

Total thyroidectomy is more cost-effective than radioactive iodine as an alternative to antithyroid medication for Graves' disease.
PubMed 文献 · Surgery · 2022-10-05

该研究采用马尔可夫决策分析模型,模拟药物难治性格雷夫斯病患者接受放射性碘治疗或全甲状腺切除术的临床结局与成本。结果显示全甲状腺切除术获得23.6个质量调整生命年,放射性碘为20.9个,增量成本效益比为每质量调整生命年2982美元,手术在88.2%的模拟中更具成本效益。

要点

  • 全甲状腺切除术较放射性碘治疗获得更多质量调整生命年(23.6 vs 20.9)。
  • 增量成本效益比为每质量调整生命年2982美元,远低于10万美元/质量调整生命年的支付意愿阈值。
  • 模型结果主要由治疗后生活质量驱动,并发症发生率及其对生活质量的影响也有贡献。

核心结论

  • 对于不能耐受或对抗甲状腺药物难治的格雷夫斯病患者,全甲状腺切除术比放射性碘治疗更具成本效益。

研究设计与样本

  • 研究采用马尔可夫决策分析模型,模拟药物难治性格雷夫斯病接受放射性碘治疗或全甲状腺切除术的临床结局与成本。
  • 并发症发生率和效用值来源于已发表数据,成本取自国家Medicare报销费率。
  • 进行了单因素、双因素和概率敏感性分析,支付意愿阈值设为每质量调整生命年100000美元。

主要发现

  • 全甲状腺切除术获得23.6个质量调整生命年,放射性碘治疗获得20.9个质量调整生命年。
  • 增量成本效益比为每质量调整生命年2982美元,表明手术相对于放射性碘治疗具有高度成本效益。
  • 在88.2%的模型模拟中,手术比放射性碘治疗更具成本效益。
  • 敏感性分析表明模型结局主要由治疗后生活质量驱动,治疗并发症发生率及其对生活质量的影响也有贡献。

关键数值与推荐

  • 支付意愿阈值设定为每质量调整生命年100000美元。
  • 全甲状腺切除术与放射性碘治疗的增量成本效益比为每质量调整生命年2982美元。

临床怎么用

  • 对于不能耐受或对抗甲状腺药物难治的格雷夫斯病患者,可优先考虑全甲状腺切除术而非放射性碘治疗。
  • 决策时应重视治疗后生活质量的差异,并充分评估并发症风险及其对生活质量的影响。

局限性

  • 研究为基于模型的经济学评价,并发症发生率和效用值来源于已发表数据,可能存在不确定性。
  • 未来研究应验证两种治疗方式之间报告的生活质量差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with Graves' disease treated with radioactive iodine report worse quality of life than those treated by thyroidectomy. However, radioactive iodine is often selected due to lower risk of complications and lower cost. The objective of this study was to estimate the cost-effectiveness of radioactive iodine versus total thyroidectomy for treatment of Graves' disease. METHODS: A Markov decision-analytic model was created to simulate clinical outcomes and costs of medication-refractory Graves' disease treated with radioactive iodine or total thyroidectomy. Complication rates and utilities were derived from published data. Costs were extracted from national Medicare reimbursement rates. We conducted 1-way, 2-way, and probabilistic sensitivity analyses to identify factors that influence cost-effectiveness and reflect uncertainty in model parameters. The willingness-to-pay threshold was set at $100,000/quality-adjusted life-years. RESULTS: Total thyroidectomy yielded 23.6 quality-adjusted life-years versus 20.9 quality-adjusted life-years for radioactive iodine. The incremental cost-effectiveness ratio was $2,982 per quality-adjusted life-years, indicating that surgery is highly cost-effective relative to radioactive iodine. Surgery was more cost effective than radioactive iodine in 88.2% of model simulations. Sensitivity analyses indicate that the model outcomes are driven predominantly by posttreatment quality of life, with contributing effects from rates of treatment complications and the impact of these complications on quality of life. CONCLUSION: For patients with Graves' disease who either cannot tolerate or are refractory to antithyroid drugs, thyroidectomy is more cost-effective than radioactive iodine. Future research should validate reported differences in quality of life between these 2 treatment modalities.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Ma EZ, Kuo JH, Malek R, et al. Total thyroidectomy is more cost-effective than radioactive iodine as an alternative to antithyroid medication for Graves' disease. Surgery. 2022. PMID: 36208983. doi:10.1016/j.surg.2022.06.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。